Physician profile
Calvin L Gibson
NPI 1134102874
$9,244.47
in general payments reported to CMS, 2019-2025
38 companies · $582 in 2025
The $582 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,643 · 2020: $1,458 · 2021: $741 · 2022: $1,581 · 2023: $1,432 · 2024: $1,807 · 2025: $582.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,721 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,720.58 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $100.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,880.67 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $1,223.43 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $993.34 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $553.85 | 2019-2024 | Shingrix, Trelegy Ellipta, Arexvy |
| Pfizer INC. | $486.40 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $394.59 | 2019-2025 | Gardasil 9, Verquvo, Gardasil |
| Amarin Pharma, INC. | $371.53 | 2019-2022 | |
| Amgen INC. | $335.92 | 2019-2025 | Repatha, Otezla, Repatha |
| Abbvie INC. | $332.11 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $287.60 | 2019-2024 | Jardiance |
| Exact Sciences Corporation | $242.82 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbott Laboratories | $236.37 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Medicure Pharma INC. | $100.17 | 2024 | Zypitamag |
| Sanofi-Aventis U.S. LLC | $96.02 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $82.36 | 2022-2024 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Calvin Gibson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.